UroGen Pharma’s (URGN) “Buy” Rating Reiterated at D. Boral Capital

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a report issued on Monday,Benzinga reports. They currently have a $25.00 price target on the stock. D. Boral Capital’s price target indicates a potential upside of 131.05% from the company’s previous close.

A number of other brokerages also recently issued reports on URGN. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $64.00 price objective on shares of UroGen Pharma in a research report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $38.20.

UroGen Pharma Trading Up 9.1 %

NASDAQ:URGN opened at $10.82 on Monday. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm has a 50-day moving average of $10.45 and a 200-day moving average of $11.70. The company has a market cap of $253.77 million, a PE ratio of -3.43 and a beta of 1.12. UroGen Pharma has a one year low of $9.03 and a one year high of $20.70.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The firm had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million. As a group, equities research analysts expect that UroGen Pharma will post -3.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the transaction, the insider now owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS purchased a new stake in shares of UroGen Pharma during the 4th quarter valued at approximately $59,000. Lazard Asset Management LLC bought a new position in UroGen Pharma in the 4th quarter worth approximately $67,000. BNP Paribas Financial Markets boosted its holdings in UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after buying an additional 5,890 shares during the period. Aquatic Capital Management LLC bought a new position in UroGen Pharma in the 4th quarter worth approximately $101,000. Finally, Oppenheimer & Co. Inc. bought a new position in UroGen Pharma in the 4th quarter worth approximately $126,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.